Can BPH urinary symptoms occur despite optimal PSA?

Lower urinary tract symptoms (LUTS) in benign prostatic hyperplasia (BPH) frequently diverge from prostate-specific antigen (PSA) levels, as PSA primarily reflects static epithelial volume rather than dynamic physiological drivers.

Pathophysiological mechanisms of LUTS

• Hormonal and Inflammatory Signaling: An age-related shift toward estrogen dominance activates stromal estrogen receptor alpha ($ER\alpha$) over epithelial $ER\beta$. This altered androgen-estrogen balance regulates stromal inflammatory gene expression, releasing cytokines, prostaglandins, and reactive oxygen species that alter bladder afferent nerve signaling.
• Neuromuscular and Smooth-Muscle Tone: Local prostatic inflammation directly promotes tissue remodeling, fibrosis, and smooth muscle hypercontractility. Concurrently, sympathetic autonomic nervous system input drives contraction of prostatic and bladder neck smooth muscle via $\alpha_1$-adrenergic receptors, escalating outflow resistance.
• The PSA Disconnect: Because these dynamic processes—including inflammatory cytokine release, detrusor overactivity, and $\alpha_1$-mediated dynamic obstruction—occur independently of total epithelial volume, severe urinary symptoms can persist or develop even when PSA levels remain within optimal ranges.

Bottom line

• BPH urinary symptoms are driven by dynamic, non-volume-dependent pathways—specifically $ER\alpha$ activation, local inflammatory signaling, and sympathetic $\alpha_1$-adrenergic smooth-muscle tone—meaning significant LUTS can persist even when PSA is within an optimal range.